The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...

More and more studies show that men face risks of cancer from BRCA1 and BRCA2 genetic mutations that are most often associated with breast and ovarian cancers in women. According to a July 25 JAMA ...

Jen Culton learned she had the BRCA1 gene mutation after her older sister's breast-cancer diagnosis. She decided to have two of her daughters tested; one daughter also has the BRCA1 gene mutation.

Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma In total, 445 patients were sampled following a ...

Lynparza significantly improves iDFS, DDFS, and OS in BRCA1/2 mutation-positive, HER2-negative high-risk breast cancer patients. The trial's six-year analysis shows consistent benefits across all ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.